RxDoctor Payments Data

Anthony Davis, MD

Family Medicine · Lindale, TXNPI 1962446898

Payments from drug & device makers

$18,662in general payments, 2019–2025

Across 728 payments — averaging $25.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • Amgen$4K
  • Novo Nordisk$1K
  • Lilly USA, LLC$831
  • Boehringer Ingelheim$728
  • AbbVie$727
  • plus $7K from 53 others

What the payments were for

  • Consulting fees$2,83515%
  • Speaking & faculty fees$3,75020%
  • Food & beverage$11,90964%
  • Education$1681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer75$4,871
Amgen65$3,658
Novo Nordisk94$1,102
Lilly USA, LLC58$831
Boehringer Ingelheim45$728
AbbVie(2 entities)39$727
Bayer49$705
Amarin Pharma, Inc.31$649
Novartis32$593
AstraZeneca32$563
Kowa Pharmaceuticals America, Inc.26$457
Teva Pharmaceuticals USA, Inc.17$386
Medicure Pharma Inc.3$302
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$232
Exact Sciences11$207
GSK9$169
Corcept Therapeutics5$154
Sunovion Pharmaceuticals Inc.10$144
Johnson & Johnson8$119
Astellas Pharma US Inc2$118
Antares Pharma, Inc.6$117
Idorsia Pharmaceuticals US Inc8$115
Otsuka America Pharmaceutical, Inc.5$110
Lundbeck LLC5$109
Takeda Pharmaceuticals U.S.A., Inc.7$102
Biohaven Pharmaceuticals, Inc.4$100
Hologic Sales And Service, LLC1$93
Biohaven Pharmaceutical Holding Company Ltd.4$92
Phathom Pharmaceuticals, Inc.5$88
Smith+Nephew5$82
Merz North America, Inc.1$75
Eisai Inc.4$73
Merck4$64
Mylan Specialty L.p.3$56
Esperion Therapeutics, Inc.3$54
Axsome Therapeutics, Inc.2$51
Arbor Pharmaceuticals, Inc.4$49
Neurocrine Biosciences, Inc.2$36
Inspire Medical Systems, Inc.2$36
Boston Scientific2$34
Clarus Therapeutics Inc.2$34
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$30
Ultragenyx Pharmaceutical Inc.2$30
Nalpropion Pharmaceuticals LLC2$29
Avanir Pharmaceuticals, Inc.2$29
Nevro Corp.2$28
Therapeuticsmd, Inc.2$28
Sumitomo Pharma America, Inc.1$26
Supernus Pharmaceuticals, Inc.1$23
Abiomed1$21
Tolmar, Inc.1$19
Paratek Pharmaceuticals, Inc.1$18
Corium, LLC1$18
Acella Pharmaceuticals, LLC1$17
Halozyme Inc1$16
Sanofi-aventis U.S. LLC1$15
Xeris Pharmaceuticals, Inc.1$13
Acerus Pharmaceuticals Corporation1$12
Athena Bioscience, LLC1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,662 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$976,036
Medicare patients
1,051
Services billed
29,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban509$229,050
OzempicSemaglutide129$131,242
IngrezzaValbenazine Tosylate11$96,957
XareltoRivaroxaban87$73,497
MounjaroTirzepatide54$70,821
JardianceEmpagliflozin92$66,675
XifaxanRifaximin15$43,722
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$32,170
GlyxambiEmpagliflozin/Linagliptin33$21,574
TrulicityDulaglutide23$20,800
FarxigaDapagliflozin Propanediol19$20,119
Repatha SureclickEvolocumab20$18,378
QuliptaAtogepant13$16,497
JanuviaSitagliptin Phosphate11$15,627
Praluent PenAlirocumab19$13,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$4,871$229,050509 claims
Novo NordiskOzempic$1,102$131,242129 claims
Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat, Synjardy$728$105,234157 claims
Neurocrine Biosciences, Inc.Ingrezza$36$96,95711 claims
Lilly USA, LLCMounjaro, Trulicity$831$91,62177 claims
Johnson & JohnsonXarelto$119$73,49787 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$232$43,72215 claims
GSKTrelegy Ellipta$169$32,17030 claims
AstraZenecaFarxiga$563$20,11919 claims
AbbVieQulipta$727$16,49713 claims
MerckJanuvia$64$15,62711 claims
Sanofi-aventis U.S. LLCMultaq$15$12,80718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lindale

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →